Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.58 |
| ▸ | NOS1 | P29475 | 5/20 | 0.58 |
| ▸ | NOS3 | P29474 | 4/20 | 0.58 |
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | ARG2 | P78540 | 4/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358975 | 1.00 | NOS2 (0.58) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL1527409 | 1.00 | NOS2 (0.58) | NOS2NOS1NOS3GSRARG2 | |
| Hydrochloric Acid SCHEMBL15091324 | 0.98 | NOS2 (0.56) | NOS2NOS1NOS3GSRARG2 | |
| Hydrochloric Acid SCHEMBL920513 | 0.98 | NOS2 (0.56) | NOS2NOS1NOS3GSRARG2 | |
| Hydrochloric Acid SCHEMBL15091326 | 0.98 | NOS2 (0.56) | NOS2NOS1NOS3GSRARG2 | |
| Acetic Acid SCHEMBL919118 | 0.96 | NOS2 (0.54) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL1527395 | 0.94 | NOS2 (0.65) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL1527394 | 0.94 | NOS2 (0.65) | NOS2NOS1NOS3GSRARG2 | |
| SCHEMBL25629375 | 0.94 | NOS2 (0.65) | NOS2NOS1NOS3GSRARG2 | |
| Hydrochloric Acid SCHEMBL8127399 | 0.92 | NOS2 (0.62) | NOS2NOS1NOS3GSRARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100273-A1 | METHOD FOR PRODUCING USEFUL SUBSTANCE, CULTURE SOLUTION FOR CULTURING ALGAE, APPARATUS FOR PRODUCING USEFUL SUBSTANCE, AND ALGAE CONTAINING USEFUL SUBSTANCE | ＮＴＴ株式会社 | 2026-05-15 | — | — | WO | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | claimed |
| EP-4457514-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | claimed |
| US-20230390346-A1 | PROBIOTIC BACILLUS COMPOSITIONS AND METHODS OF USE | BIOMEDIT, LLC | 2023-12-07 | — | — | US | claimed |
| EP-4216726-A1 | PROBIOTIC BACILLUS COMPOSITIONS AND METHODS OF USE | Biomedit, LLC (US) | 2023-08-02 | — | — | EP | claimed |
| WO-2023126759-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2023-07-06 | — | — | WO | claimed |
| WO-2023126758-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2023-07-06 | — | — | WO | claimed |
| US-20230204605-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| EP-3313845-A1 | CONJUGATES OF CYSTEINE ENGINEERED ANTIBODIES | ImmunoGen, Inc. (US) | 2018-05-02 | — | — | EP | claimed |
| EP-3188733-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | ImmunoGen, Inc. (US) | 2017-07-12 | — | — | EP | claimed |
| WO-2017004025-A1 | CONJUGATES OF CYSTEINE ENGINEERED ANTIBODIES | IMMUNOGEN, INC. (US) | 2017-01-05 | — | — | WO | claimed |
| WO-2016036794-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. (US) | 2016-03-10 | — | — | WO | claimed |
| EP-2621919-B1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-13 | — | — | EP | claimed |
| EP-2961435-A2 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | ImmunoGen, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150359904-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. | 2015-12-17 | — | — | US | claimed |
| WO-2014194030-A2 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. (US) | 2014-12-04 | — | — | WO | claimed |
| WO-2014134486-A2 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. (US) | 2014-09-04 | — | — | WO | claimed |
| WO-2014134457-A2 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. (US) | 2014-09-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150359904-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | CD47, PAICS, MCL1 | NOS2 4762/4885NOS1 4753/4885NOS3 4798/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | NOS2 1516/4885NOS1 1882/4885NOS3 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.